Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + TP chemotherapy for recurrent/metastatic HNSCC (single-arm phase II)
ChiCTR2600119085Phase 2Recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, anlotinib, paclitaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 2 more, sponsored by Mianyang Central Hospital. Primary endpoint: tumor lesion response. Started Feb 2026; status: recruiting.
02
Drugs
sintilimabanlotinibpaclitaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on ChiCTR2600119085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119085.